Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > No release date yet for Q4 and Full yr 2022 results

<< Previous

Bullboard Posts

Next >>

Comment by GJS471on Feb 09, 2023 2:04pm

104 Views

Post# 35277747

RE:RE:No release date yet for Q4 and Full yr 2022 results

My apologies, you are absolutely correct. I thought there was a date announcing the release of the YE for CPH last year but all I see is the actual release date.

I look forward to the results this year and any information that may come out. I have been very long for a very long time. But the price of entry over time was not bad and it has been one of those stocks that I have believed in and stuck with. Time will tell.
Good luck to all as we see what happens.

<< Previous

Bullboard Posts

Next >>

Three point-of-sale stocks you should watch